Pablo Concepcion, MD
Interventional Pain Medicine · Pensacola, FLNPI 1043232432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Boston Scientific at 45.7% of the total. Reporting peaked in 2024 at $1,227 and has fallen 57.4% since, to $523 in 2025.
Across 125 payments — averaging $43.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$699
- Medtronic$651
- AbbVie$388
- MML US, Inc.$288
- Relievant Medsystems, Inc.$167
- plus $782 from 20 others
What the payments were for
- Food & beverage$5,461100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 37 | $2,507 |
| Abbott | 7 | $699 |
| Medtronic(2 entities) | 15 | $651 |
| AbbVie(2 entities) | 20 | $388 |
| MML US, Inc. | 5 | $288 |
| Relievant Medsystems, Inc. | 2 | $167 |
| Novartis | 5 | $116 |
| Nevro Corp. | 5 | $115 |
| Fidia Pharma USA Inc. | 6 | $104 |
| Lilly USA, LLC | 1 | $66 |
| SPR Therapeutics, Inc | 2 | $64 |
| Nalu Medical, Inc. | 3 | $37 |
| Globus Medical | 1 | $33 |
| Averitas Pharma Inc. | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 2 | $26 |
| Pfizer | 2 | $26 |
| Amgen(2 entities) | 2 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $13 |
| Neuronetics, Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WaveWriter Alpha Prime 16$706
- Proclaim Family of SCS IPGs$409
- WAVEWRITER ALPHA$355
- Intracept$287
- Superion Indirect Decompression System$266
- ReActiv8$264
- KYPHON EXPRESS II KYPHOPAK TRAY$146
- INTELLIS ADAPTIVESTIM$140
- INTELLIS$138
- S-Series SCS Leads$133
- ETERNA$123
- SPECTRA WAVEWRITER$108
- COVEREDGE$108
How this compares
$5,482 in reported general payments places this provider in the 55th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,554 | $40,550 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 991 | $39,387 |
| Buprenorphine | 45 | $10,256 |
| Pregabalin | 347 | $9,260 |
| MovantikNaloxegol Oxalate | 14 | $5,686 |
| Gabapentin | 315 | $5,161 |
| Morphine Sulfate ErMorphine Sulfate | 230 | $4,448 |
| Naloxone Hcl | 65 | $3,996 |
| Tramadol Hcl ErTramadol Hcl | 56 | $3,572 |
| Lidocaine | 23 | $3,304 |
| Tizanidine Hcl | 118 | $3,135 |
| Fentanyl | 29 | $2,825 |
| ButransBuprenorphine | 11 | $2,824 |
| Tramadol Hcl | 256 | $2,497 |
| Diclofenac Sodium | 29 | $1,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $21 | $11,11977 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Pensacola
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.